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Chronic kidney disease is a major cause of morbidity and mortality, 
affecting 10–20% of the world population, with glomerulonephritis 
accounting for a considerable proportion of cases1–3. IgA nephro­
pathy is the most common form of glomerulonephritis and the most 
common cause of kidney failure among Asian populations2,4. The 
diagnosis of IgA nephropathy requires documentation by kidney 
biopsy demonstrating proliferation of the glomerular mesangium 
with deposition of immune complexes predominantly composed of 
immunoglobulin and complement C3 proteins3,5,6. Registry data as 
well as autopsy and kidney­donor biopsy series suggest substantial 
variation in the prevalence of IgA nephropathy among populations 
with different ancestries: it is most frequent among Asians, with a 
disease prevalence as high as 3.7% detected among Japanese kidney 
donors7, but is rare among individuals of African ancestry5 and is of 
intermediate prevalence among Europeans (up to 1.3%)6.
The pathogenesis of IgA nephropathy is uncertain8,9. The find­
ing of IgA1 glycosylation abnormalities among European, Asian and 
African­American populations suggests a shared pathogenesis among 
different groups10–15. Moreover, familial aggregation of IgA nephro­
pathy has been reported among people of all ancestries, suggesting 
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a genetic component to the disease8,16. So far, linkage studies have 
identified several loci predisposing individuals to IgA nephropathy, 
but the underlying genes are not known8,16–18. A single, unreplicated 
genome­wide association study (GWAS) in a small European cohort 
(533 cases) has reported association of IgA nephropathy with the 
major histocompatibility complex (MHC)19.
We report a GWAS for IgA nephropathy in a cohort of 3,144 IgA 
nephropathy cases of Chinese and European ancestry, leading to the 
identification of five loci for this disease.
RESULTS
Study design and genotyping of discovery cohort
To detect loci conferring susceptibility to IgA nephropathy, we carried 
out a two­stage GWAS (Table 1). In the discovery phase, we carried out 
genome­wide genotyping on the Illumina 610 Quad platform in 1,228 
biopsy­proven IgA nephropathy cases and 966 healthy controls of Chinese 
Han ancestry recruited from Beijing (Table 1 and Supplementary 
Table 1). We further evaluated the top signals in the discovery phase 
in an independent cohort of Han Chinese descent (Shanghai cohort, 
740 cases and 750 controls) and a European cohort of Italian and North 
American origin (combined by stratified analysis, 1,273 cases and 1,201 
controls). Subsequently, we analyzed the Beijing, Shanghai and European 
cohorts together to identify genome­wide significant loci.
Genome-wide association analysis
In analysis of genome­wide genotyping data, we applied quality con­
trol filters, leading to elimination of 5% of samples because of low 
call rate, duplication, cryptic relatedness or gender mismatch and 
16.8% of markers primarily because of low minor allelic frequency 
(<0.01, see Supplementary Note and Supplementary Table 2). 
After quality control, the genotyping call rate was 0.9992. We next 
applied the standard 1­degree­of­freedom Cochran­Armitage trend 
test to analyze 498,322 SNPs in the discovery cohort of 1,194 cases 
(650 males and 544 females, average age 31.1 years) and 902 controls (608 
males and 294 females, average age 31.5 years). The quantile­quantile 
plot showed no global departure from the expected distribution of 
P values and the inflation factor (λ) was 1.024, indicating negligible popu­
lation stratification (Supplementary Fig. 1 and Fig. 1). Accordingly, 
principal component analysis (PCA) indicated 
that cases and controls were matched along 
the axes of statistically significant principal 
components, and PCA correction did not 
substantially change the distribution of the 
association statistic or the genomic inflation 
factor (λ = 1.022; Supplementary Fig. 2 and 
Supplementary Table 3). We concluded that 
our association results were not biased by 
differences in ancestry or population structure 
between cases and controls.
The genome­wide association analysis 
showed 27 SNPs exceeding genome­wide 
thresholds for significance (P ≤ 5 × 10−8; 
Fig. 1). These 27 signals all resided in a 
0.54­Mb interval within the MHC on chromosome 6p21, with the top 
signal at rs9275596 (P = 1.9 × 10−12). Notably, 14 MHC SNPs with 
suggestive P values (P = 5 × 10−6 to P = 1 × 10−4) showed little or no 
linkage disequilibrium (LD) with rs9275596 (Fig. 2a).
Follow-up of top signals from discovery stage
After we removed MHC SNPs, additional loci remained that showed 
departure from the expected P­value distribution. We ranked signals 
on the basis of the false discovery rate and chose to follow up loci with 
P ≤ 1.3 × 10−5, corresponding to a Q value ≤ 0.10 (Supplementary 
Fig. 3)20. Power calculations indicated that this strategy would pro­
vide 80% power to detect loci with allelic frequencies >0.10 and rela­
tive risk >1.5 with genome­wide significance (P < 5 × 10−8) in the 
combined cohort (Supplementary Table 4). In total, 65 SNPs from 
ten distinct loci met these criteria (including three potentially inde­
pendent loci in MHC and two in the chromosome 22q12.2 interval). 
We genotyped the top­scoring SNPs and one additional SNP from 
each of these intervals in follow­up cohorts (20 SNPs total in 3,870 
individuals after quality control; Table 1). We carried out tests of 
association within each cohort, followed by a combined analysis with 
the discovery cohort using Mantel’s extension of Cochran­Armitage 
trend test (Table 2 and Supplementary Table 5).
Five of the ten loci selected for follow up surpassed the threshold 
for significant genome­wide association: three loci within 6p21, one 
locus at 1q32 and one locus at 22q12.2 (Table 2 and Supplementary 
Tables 5,6). Each signal had significant association with consistent 
effect size for the same risk allele in each individual cohort, with little 
evidence for heterogeneity.
The strongest association in the combined cohort was located 
within a ~170­kb interval that includes HLA-DRB1, HLA-DQA1 and 
HLA-DQB1 (rs9275596, odds ratio (OR) = 0.63, P = 1.6 × 10−26). This 
SNP has genome­wide significance with a consistent effect size in each 
cohort (Table 2 and Fig. 2b) and has strong supporting association 
from a nearby SNP in strong LD (rs2856717).
This locus, however, did not explain all of the signal at 6p21. 
Conditioning for the effect of rs9275596 eliminated evidence for 
association for the majority of SNPs in close proximity, however two 
distinct loci maintained genome­wide significance. The second inde­
pendent locus is defined by rs9357155 (which has an r2 = 0.01 for 
correlation with rs9275596 in the combined cohort) and has an OR of 
0.74 and a P value of 6.9 × 10−9 for association with IgA nephropathy 
after conditional analysis (Table 3 and Fig. 2c). This SNP lies in a 
~100­kb segment of LD and lies 128 kb centromeric to rs9275596. This 
LD segment contains the genes TAP2, TAP1, PSMB8 and PSMB9, and 
the supporting SNP in this region (rs2071543) is a missense variant 
in PSMB8 (p.Gln49Lys) that is at a position completely conserved 
table 1 summary of study cohorts
Cohort Ancestry
Genotyped After quality control
Cases Controls Cases Controls
Discovery cohort Han Chinese 1,228 966 1,194 902
Follow-up cohort 1 Han Chinese 740 750 712 748
Follow-up cohort 2 European 1,273 1,201 1,238 1,172
All cohorts combined 3,241 2,917 3,144 2,822
Figure 1 Manhattan plot of P values for SNP associations to IgA nephropathy. Observed P values 
versus chromosomal location; highlighted are the ten independent loci followed up in additional 
cohorts. Dashed line, follow-up threshold.
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among all orthologs (most distantly related ortholog is in platypus; 
Tables 2,3, Fig. 2c and Supplementary Tables 7,8).
After we conditioned for the effects of both rs9275596 and 
rs9357155, we found that a third locus within MHC, defined by 
rs1883414, which lies 400 kb centromeric to rs9275596 (and which 
showed r2 = 0.005 and r2 = 0.002 with rs9275596 and rs9357155, 
respectively), showed a conditioned OR of 0.77 and P value of 3.1 × 
10−8 for association (Table 3). This signal, in the region of HLA-DPA1, 
HLA-DPB1 and HLA-DPB2, is supported by a second SNP (rs3129269) 
and showed consistent effect size across cohorts (Tables 2,3, Fig. 2d, 
and Supplementary Tables 7,8).
To better delineate the risk associated with the MHC region and 
detect potential functional variants, we imputed classical HLA alleles 
in the discovery cohort21 (Supplementary Table 9). This showed a 
genome­wide significant association with a protein­altering variant of 
known functional importance, the DQB1*0602 allele (OR = 0.47, P = 
6.6 × 10−9). DQB1*602 is in strong LD with another functional allele, 
DRB1*1501, but conditional analysis suggested that DQB1*602 best 
explains this association signal (Supplementary Table 10). The strength 
of the DQB1*602 association is probably underestimated because of the 
limitations of current imputation algorithms (sensitivity of 56.6% for 
detection of the DQB1*602 allele; Supplementary Table 11).
A major signal outside the MHC locus resided in a 100­kb segment 
on chromosome 1q31­q32.1 containing CFH (encoding comple­
ment factor H) and the related CFHR3, CFHR1, CFHR4, CHFR2 and 
CFHR5 genes (rs6677604, OR = 0.68, P = 3.0 × 10−10 in the combined 
cohort). This locus was also the top signal in our genome­wide copy 
number polymorphism (CNP) analysis (Supplementary Fig. 4 and 
Supplementary Table 12). The top SNP, rs6677604, is located in 
intron 12 of CFH and is supported by multiple highly correlated SNPs 
(Fig. 3a and Table 2). After controlling for rs6677604, there were no 
other independent signals in the entire CFH region. The association 
results at rs6677604 were far less significant under a recessive model 
(P = 5.6 × 10−5), supporting an additive risk. The rs6677604 A allele is 
protective in all three cohorts but has a much higher allele frequency 
in Europeans (0.23 in European controls versus 0.07 in Chinese con­
trols; Table 2). This allele perfectly tags a common deletion spanning 
CFHR1 and CFHR3 (CFHR1,3∆)22,23. We confirmed the association 
of the rs6677604 A allele with CFHR1,3∆ in our cohort: PCR of 
multiple amplicons within CFHR1 and CFHR3 failed, and we did not 
table 2 Association results for ten sNPs representing five independent regions that reach genome-wide significance in combined 
analyses
Beijing discovery cohorta  
n = 2,096 (1,194 cases,  
902 controls)
Shanghai replication cohorta  
n = 1,460 (712 cases,  
748 controls)
European replication cohortb  
n = 2,410 (1,238 cases,  
1,172 controls)
All cohorts combinedb  
n = 5,966 (3,144 cases,  
2,822 controls)
Chr.
Location  
(kb)
SNP  
(minor  
allele)
MAF  
(cases/
controls) OR P
MAF  
(cases/ 
controls) OR P value
MAF  
(cases/
controls) OR P
OR
P Q
Per  
allele Het. Hom.
1 194,918 rs3766404 (c) 0.052/0.086 0.59 1.84 × 10−5 0.078/0.080 0.98 8.18 × 10−1 0.12/0.14 0.82 1.46 × 10−2 0.77 0.79 0.45 4.24 × 10−5 0.01*
1 194,953 rs6677604 (A) 0.041/0.073 0.55 1.20 × 10−5 0.052/0.070 0.73 3.22 × 10−2 0.17/0.23 0.71 1.19 × 10−5 0.68 0.69 0.41 2.96 × 10−10 0.17
6 32,778 rs2856717 (t) 0.19/0.26 0.66 3.31 × 10−8 0.14/0.20 0.69 1.51 × 10−4 0.28/0.33 0.77 3.32 × 10−6 0.73 0.69 0.59 8.44 × 10−16 0.44
6 32,789 rs9275596 (c) 0.14/0.22 0.56 1.91 × 10−12 0.09/0.16 0.54 6.29 × 10−8 0.20/0.27 0.70 7.40 × 10−10 0.63 0.62 0.43 1.59 × 10−26 0.31
6 32,917 rs9357155 (A) 0.15/0.20 0.69 5.19 × 10−6 0.12/0.18 0.64 1.79 × 10−5 0.11/0.13 0.77 8.26 × 10−4 0.71 0.66 0.62 2.11 × 10−12 0.35
6 32,919 rs2071543 (A) 0.16/0.22 0.70 7.19 × 10−6 0.14/0.20 0.65 1.59 × 10−5 0.12/0.14 0.81 1.66 × 10−3 0.73 0.67 0.64 5.77 × 10−12 0.27
6 33,194 rs1883414 (t) 0.19/0.24 0.73 3.26 × 10−5 0.17/0.20 0.82 3.55 × 10−2 0.29/0.33 0.82 2.17 × 10−4 0.78 0.77 0.61 4.84 × 10−9 0.55
6 33,205 rs3129269 (t) 0.21/0.27 0.73 1.32 × 10−5 0.20/0.23 0.83 3.48 × 10−2 0.33/0.38 0.83 6.67 × 10−4 0.79 0.79 0.61 8.54 × 10−9 0.42
22 28,824 rs2412971 (A) 0.31/0.39 0.72 8.21 × 10−7 0.24/0.28 0.83 2.79 × 10−2 0.46/0.51 0.82 1.61 × 10−3 0.80 0.75 0.66 1.86 × 10−9 0.29
22 28,859 rs2412973 (A) 0.32/0.39 0.73 1.91 × 10−6 0.26/0.30 0.83 2.68 × 10−2 0.46/0.51 0.83 2.09 × 10−3 0.80 0.76 0.66 4.46 × 10−9 0.28
The per-allele, heterozygote (het.) and homozygote (hom.) ORs are indicated for the combined cohort. MAF, minor allele frequency; Het., heterozygous; Hom., homozygous.
aCochran-Armitage trend test. bStratified analysis using Mantel’s extension of Cochran-Armitage trend test. Chr, chromosome. Q, P value for the Cochran’s Q statistic. *Significant heterogeneity (P < 0.05).
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Figure 2 High-resolution view of MHC locus.  
x axes, physical distance (kb); left y axes, −log P 
for association statistics. The −log P values in 
the discovery and combined cohorts are blue 
circles and red diamonds, respectively. Right  
y axes, average recombination rates based on 
the phased HapMap haplotypes. Recombination 
rates, light blue lines. (a) The three intervals 
associated with IgA nephropathy reside within 
a 0.54 Mb segment on chromosome 6. Shaded 
areas correspond to regional plots in b–d.  
(b) Regional plot for interval containing HLA-DQB1, 
HLA-DQA1 and HLA-DRB1. The classical 
HLA alleles imputed in the discovery cohort 
(green triangles) formed a protective haplotype, 
DQB1*0602-DQA1*0102-DRB1*1501.  
(c) Regional plot for the second MHC interval: 
SNPs typed in the combined cohorts reside within 
PSMB8. (d) Regional plot for the HLA-DPB2, 
HLA-DPB1 and HLA-DPA1 interval. Bottom of 
b–d, LD heat maps (D′) calculated based on the 
genotype data of the Beijing cohort.
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detect the CFHR1 protein in serum from all AA homozygotes tested 
(Supplementary Fig. 5). We evaluated evidence for association of 
IgA nephropathy with alleles in CFH that confer risk of age­related 
macular degeneration (AMD) and found no contribution to risk (for 
example, the p.Tyr402His variant, tagged by rs10801555, showed OR = 
1.0 and P = 0.99 in discovery cohort; Fig. 3b). Haplotype­based 
analysis in the Beijing discovery cohort indicated protection by the 
haplotype containing the rs6677604 A allele (OR = 0.56, P = 1 × 
10−6 versus all other haplotypes in the discovery cohort; Fig. 3b and 
Supplementary Fig. 6) but no significant effect of other haplotypes.
The fifth signal in the GWAS resided in an intronic SNP in 
HORMAD2 on chromosome 22.q12.2 (rs2412971, OR = 0.80, P = 1.9 × 
10−9) and was supported by a second SNP within 35 kb of this sig­
nal (rs2412973, OR = 0.80, P = 4.5 × 10−9). After controlling for 
rs2412971, there were no other independent signals in this region. 
The association extends across a large LD segment that encompasses 
genes including HORMAD2, MTMR3, LIF and OSM (Fig. 3c).
Cumulative effects on disease risk
To determine the cumulative risk conferred by these loci, we computed 
a genetic risk score, calculated as the weighted sum of the number of 
protective alleles multiplied by the log of the OR for each of the indi­
vidual loci (Table 4 and Supplementary Tables 13,14). The disease 
risk varied up to tenfold between individuals with no protective alleles 
and those with five or more. The risk score model was similar in all 
cohorts and collectively explained 5–7% of the variation in disease 
risk in the Chinese cohorts and ~4% of the risk in the European cohort 
(Table 4). The risk score did not reproducibly correlate with any of the 
parameters of disease severity, such as estimated glomerular filtration 
rate, degree of proteinuria or histologic severity grade.
Most notably, consistent with the higher prevalence of IgA nephro­
pathy in Asians, the frequency of protective alleles was significantly 
lower in the Chinese cohort compared with the European group. The 
differences in distribution of protective alleles were highly significant 
between the Asian and European cohorts (Fig. 4a, P = 4.8 × 10−72 and 
P = 6.4 × 10−60 for differences within cases and controls, respectively). 
To confirm this finding in independent populations, we examined 
three HapMap groups and similarly found that frequencies of risk 
alleles correlate with disease frequency among these populations: risk 
allele frequencies were highest in Asians, intermediate in Europeans 
and lowest in Africans (Fig. 4b and Supplementary Fig. 7). For 
table 3 stepwise conditional analysis of association among the signals in the HlA region
Test SNP
Conditioning  
SNP(s)
Beijing discovery cohort n = 2,096 
(1,194 cases, 902 controls)
Shanghai follow-up cohort  
n = 1,460 (712 cases,  
748 controls)
European follow-up cohort  
n = 2,410 (1,238 cases,  
1,172 controls)
All cohorts combined n = 5,966 
(3,144 cases, 2,822 controls)
Unconditioned P Conditioned P Unconditioned P Conditioned P Unconditioned P Conditioned P Unconditioned P Conditioned P
rs2856717 3.30 × 10−8 0.280 1.51 × 10−4 0.271 3.32 × 10−6 0.354 8.44 × 10−16 0.114
rs9275596
rs9275596
1.91 × 10−12 NA 6.29 × 10−8 NA 7.40 × 10−10 NA 1.59 × 10−26 NA
rs9357155 5.19 × 10−6 2.29 × 10−3 1.79 × 10−5 3.12 × 10−4 8.26 × 10−4 8.83 × 10−4 2.11 × 10−12 6.87 × 10−9
rs1883414 1.32 × 10−5 2.16 × 10−4 0.0348 0.164 6.67 × 10−4 3.64 × 10−4 8.54 × 10−9 9.94 × 10−8
rs2856717 3.30 × 10−8 0.236 1.51 × 10−4 0.225 3.32 × 10−6 0.303 8.44 × 10−16 0.0754
rs9275596 rs9275596, 1.91 × 10−12 NA 6.29 × 10−8 NA 7.40 × 10−10 NA 1.59 × 10−26 NA
rs9357155 rs9357155 5.19 × 10−6 NA 1.79 × 10−5 NA 8.26 × 10−4 NA 2.11 × 10−12 NA
rs1883414 1.32 × 10−5 7.04 × 10−5 0.0348 0.059 6.67 × 10−4 7.18 × 10−4 8.54 × 10−9 3.13 × 10−8
rs2856717 rs9275596,
rs9357155,
rs1883414
3.30 × 10−8 0.278 1.51 × 10−4 0.241 3.32 × 10−6 0.272 8.44 × 10−16 0.0760
rs9275596 1.91 × 10−12 NA 6.29 × 10−8 NA 7.40 × 10−10 NA 1.59 × 10−26 NA
rs9357155 5.19 × 10−6 NA 1.79 × 10−5 NA 8.26 × 10−4 NA 2.11 × 10−12 NA
rs1883414 1.32 × 10−5 NA 0.0348 NA 6.67 × 10−4 NA 8.54 × 10−9 NA
rs9275596 and rs2856717 represent the major HLA signal near DQB1. rs9357155 and rs1883414 represent the other two independent signals in the HLA region. NA, not applicable.
b CFHR1,3�
CFH CFHR3 CFHR1
H-1: A - G - G - G
G - A - G - G
G - G - G - T
G - G - A - G
G - G - G - G
rs
10
80
15
55
rs
66
77
60
4
rs
22
84
66
4
rs
10
65
48
9
50 kb
H-2:
H-3:
H-4:
H-5:
0.075
0.038
Freq.
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Figure 3 Analysis of the chromosome 1 and chromosome 22 loci.  
(a) Regional association plot of the chromosome 1q32 locus; although  
the most strongly associated SNP resides within CFH, it is a perfect 
proxy for CFHR1,3∆. Bottom, LD heat map (D′) calculated based on the 
genotype data of the Beijing cohort. (b) Haplotype analysis indicated 
five common haplotypes (H-1 to H-5) in the Beijing discovery cohort 
(frequency (freq.) > 0.01). The haplotype frequencies, corresponding 
tag SNPs and reported disease associations are shown22–24,36,37,41,43. 
The H2 haplotype perfectly tags CFHR1,3∆. The ORs and 95% CIs are 
calculated in reference to H-1, which has an identical frequency among 
cases and controls. ***P = 7.7 × 10−6 for comparison of H-2 versus all 
other haplotypes. (c) Regional association plot of the chromosome  
22 locus: the strongest association stems from the SNPs residing  
within HORMAD2, but the area of association spans a region over  
~0.7 Mb containing multiple genes.
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 example, the protective allele at the chromosome 1 locus has a fre­
quency of 0.08 in Asians, 0.24 in Europeans and 0.49 in Africans.
DISCUSSION
In this GWAS, we identified five loci imparting significant and con­
sistent effects on the risk of IgA nephropathy across three independent 
cohorts. These five loci explained up to a tenfold variation in interin­
dividual risk and cumulatively accounted for 4–7% of the disease vari­
ance. The effect sizes at these loci are relatively large and consistent 
across the European and Chinese cohorts, with four having inverse 
OR ≥ 1.4, which is comparable to those detected in earlier studies of 
autoimmune or inflammatory diseases21,24–30. The risk allele frequen­
cies also strongly paralleled the prevalence of IgA nephropathy among 
different populations.
We detected a major signal in the MHC region, which was identified 
but not localized in a recent GWAS with 533 affected subjects19. Our 
study of the markedly larger cohorts reported here showed that this 
signal originated from three distinct loci within HLA; we also identified 
two non­HLA loci. Evidence supporting the presence of three independ­
ent risk loci on chromosome 6p21 includes their position within distinct 
LD segments, as well as genome­wide significance after conditioning for 
the other two loci, with consistent effects within each cohort.
The strongest HLA signal was in the region of HLA-DRB1 and 
HLA-DQB1. Imputation of classical alleles suggested that this sig­
nal is fully or partially conveyed by a strong protective effect of the 
DRB1*1501-DQB1*0602 haplotype; the strength of this association 
was probably underestimated by limitations of imputation. This 
haplotype is relatively common in the European and Asian popula­
tions (frequency, ~0.1–0.2) and, in contrast to its protective effect 
for IgA nephropathy, has been associated with increased risk of 
 systemic lupus erythematosus25, multiple sclerosis31, narcolepsy32 
and hepatotoxicity from COX2 inhibitors30 but is also highly protec­
tive for type I diabetes mellitus26. This haplotype is also protective 
in selective IgA deficiency27, yet we found no association with IgA 
levels at this locus among cases (Supplementary Table 15). This 
region has a complex LD structure, and our conditional analysis 
suggests the possibility of an independent signal within this region 
(at rs9275424; Supplementary Tables 7,8). High­resolution map­
ping and direct genotyping of classical alleles will be required to 
further dissect this interval and identify the functional variant(s).
The second independent interval at 6p21 contained TAP2, TAP1, 
PSMB8 and PSMB9, interferon­regulated genes implicated in antigen 
generation and processing for presentation by MHC I molecules; they 
also have an important role in modulation of cytokine production 
and cytotoxic T­cell response33,34. PSMB8 expression is increased 
in peripheral blood mononuclear cells from individuals with IgA 
nephropathy, motivating further investigation35. To our knowledge, 
this locus has not been identified in any earlier GWAS.
The third signal at 6p21 comprised the HLA-DPA1, HLA-DPB1 
and HLA-DPB2 genes. This locus is associated with risk of chronic 
 hepatitis B infection29 (a major clinical problem in China) and sys­
temic sclerosis stratified for antibody to DNA topoisomerase I or 
autoantibodies to centromeres31, but the risk alleles associated with 
these phenotypes are not in LD with any of the IgA nephropathy 
risk alleles.
CFH has a critical role in dampening the alternative complement 
cascade through inhibition of the C3 and C5 convertases36. The func­
tions of the CFH­related proteins are less well understood36,37. Loss­
of­function mutations in CFH produce uncontrolled C3 activation, 
leading to membranoproliferative glomerulonephritis type II, which 
is pathologically distinct from IgA nephropathy36. Other rare CFH 
mutations can produce hemolytic uremic syndrome, a thrombotic dis­
order36, whereas distinct common haplotypes predispose individuals 
to AMD and susceptibility to meningococcal infection22–24. Notably, 
the CFH haplotype bearing the CFHR1,3∆ variant may be protective 
in AMD, but detection of an independent effect has been complicated 
table 4 cumulative effect of replicated loci stratified by the number of protective alleles
Beijing discovery cohort (n = 2,074)*  
1,176 cases / 898 controls
Asian replication cohort (n = 1,397)*  
685 cases / 712 controls
European replication cohort (n = 2,160)*  
1,098 cases / 1,062 controls
No. protective alleles
Frequency 
(cases/controls)
Risk score  
(mean ± s.d.) OR (95% CI)
Frequency 
(cases/controls)
Risk score  
(mean ± s.d.) OR (95% CI)
Frequency 
(cases/controls)
Risk score  
(mean ± s.d.) OR (95% CI)
0 (highest risk) 0.17/0.07 0.00 1.00 (reference) 0.24/0.13 0.00 1.00 (reference) 0.07/0.03 0.00 1.00 (reference)
1 0.31/0.26 −0.37 ± 0.09 0.50 (0.36–0.69) 0.38/0.32 −0.30 ± 0.15 0.66 (0.48–0.90) 0.19/0.12 −0.11 ± 0.04 0.59 (0.36–0.97)
2 0.29/0.29 −0.77 ± 0.14 0.40 (0.29–0.56) 0.24/0.31 −0.65 ± 0.23 0.43 (0.31–0.60) 0.26/0.24 −0.23 ± 0.05 0.39 (0.25–0.63)
3 0.16/0.20 −1.17 ± 0.15 0.31 (0.22–0.44) 0.10/0.14 −1.06 ± 0.26 0.40 (0.27–0.60) 0.26/0.30 −0.35 ± 0.06 0.30 (0.19–0.48)
4 0.06/0.12 −1.61 ± 0.17 0.20 (0.13–0.31) 0.04/0.08 −1.44 ± 0.28 0.28 (0.16–0.47) 0.15/0.19 −0.47 ± 0.06 0.28 (0.17–0.45)
≥5 (lowest risk) 0.01/0.06 −2.11 ± 0.25 0.09 (0.05–0.16) 0.004/0.03 −1.86 ± 0.36 0.10 (0.03–0.33) 0.08/0.13 −0.65 ± 0.10 0.21 (0.12–0.35)
Or changea 11.1 10.0 4.8
P valueb 6.76 × 10−27 3.13 × 10−14 6.24 × 10−17
c-statistic (95% ci)c 0.63 (0.60–0.65) 0.61 (0.58–0.64) 0.60 (0.58–0.62)
Nagelkerked r 2 0.072 0.054 0.042
*Risk scores were calculated on the basis of the ORs and allele frequencies for each specific cohort. Only individuals with nonmissing genotypes for all ten alleles were included in this analysis.
aFold-change in OR between highest- and lowest-risk group. bP value for the risk score prediction model. cC-statistic indicates the area under the receiver operating characteristic (ROC) curve for the risk score 
prediction model. dNagelkerke’s pseudo r2 indicates fraction of the variance in risk explained by the risk score model.
Figure 4 Differences in the distributions of protective alleles by subject 
ancestry. (a) Distributions of protective alleles by subject ancestry 
and case-control status. Numbers of protective alleles were scored for 
the combined Asian (n = 3,556) and European (n = 2,410) cohorts. 
Europeans harbor much greater numbers of protective alleles. The 
differences in the distribution of protective alleles between Asians and 
Europeans are highly significant within both case and control groups  
(χ2 P = 4.9 × 10−72 and P = 6.4 × 10−60 for cases and controls, 
respectively). (b) Distributions of protective alleles among the three 
HapMap populations: there were highly significant differences between 
Asian (CHB+JPT) and European (CEU, P = 1.3 × 10−3) and Asian and 
Yoruban (YRI, P = 7.1 × 10−6) populations.
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because of the presence of additional haplotypes imparting both high 
and low risk22,23. Here we found an unambiguous protective effect of 
the CFHR1,3∆–containing haplotype in IgA nephropathy, strongly 
suggesting that CFHR1,3∆ is the functional variant. Nevertheless, it 
is unclear how loss of CFHR1 and/or CFHR3 may confer protection 
for IgA nephropathy. The protective effects may be due to the com­
peting roles of CFH and CFHR1 proteins37, such that loss of CFHR1 
enhances CFH effects, reducing inflammation at tissue surfaces.
The chromosome 22q12.2 locus spans a large interval that con­
tains OSM and LIF, encoding cytokines implicated in mucosal 
immunity and inflammation. Notably, inactivation of Osm leads to 
autoimmune glomerulonephritis in mouse38. The functions of other 
genes such as HORMAD2 and MTMR3 have not been as well char­
acterized39. In addition, the rs2412973 A allele, which is protective 
for IgA nephropathy, has also been associated with increased risk 
of early­onset inflammatory bowel disease and altered expression of 
MTMR3 expression in individuals with ulcerative colitis28. This find­
ing is notable given the known clinical association between inflam­
matory bowel disease and secondary forms of IgA nephropathy, but 
the underlying signal within this locus remains to be clarified. Lastly, 
the protective allele at this locus is also associated with lower serum 
IgA levels among cases (P = 3.9 × 10−3; Supplementary Table 15 and 
Supplementary Fig. 8).
Many of the protective alleles for IgA nephropathy have been 
implicated as risk factors for other immune­mediated and infectious 
disorders, suggesting that complex selection pressures (potentially 
balancing selection) may influence the frequencies of these alleles 
among world populations. Statistical proof of balancing selection 
on allele frequencies or genotypes may be particularly challenging 
if alleles have been maintained in the population over very long evo­
lutionary periods. Notably, a recent genome­wide survey detected a 
signal of selection in the vicinity of the CFH gene cluster40, and there 
is a large difference in the frequency of the rs6677604 A allele among 
world populations (Supplementary Table 16).
The loci identified in this study clarify the genetic architecture of 
sporadic IgA nephropathy, identifying new pathogenic pathways and 
connections to other immune­mediated disorders. On the basis of our 
power calculations, we identified virtually all loci imparting an OR 
≥ 1.5 in the Chinese discovery cohort, but additional loci with large 
effects may be present among Europeans. Considering the effective­
ness of GWAS for studies of immunologic disorders22,27–31,41 and 
the increased power imparted by larger sample size42, genome­wide 
examination of larger cohorts will probably define additional genetic 
components of IgA nephropathy.
URLs. HLA genotype data of the HapMap Chinese samples, https://
www.sanger.ac.uk/HGP/Chr6/ng2006­data/; IBD software, http://
www1.cs.columbia.edu/~itsik/hla_ibd/; HapMap, http://hapmap.
ncbi.nlm.nih.gov/.
METHODS
Methods and any associated references are available in the online version 
of the paper at http://www.nature.com/naturegenetics/.
Note: Supplementary information is available on the Nature Genetics website.
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ONLINE METHODS
Genome-wide genotyping, genotype quality control and primary asso-
ciation analyses. Study populations, genome­wide genotyping and genotype 
quality control are described in the Supplementary Note and Supplementary 
Tables 1 and 2. After quality control analysis, the discovery cohort consisted 
of 1,194 cases and 902 controls genotyped with the Illumina Human 610­
Quad BeadChip. The primary genome­wide association analyses were carried 
out using PLINK v1.07 (ref. 44). We selected a standard 1­degree­of­freedom 
Cochran­Armitage trend test as the primary association test, as it demonstrates 
greater robustness to deviations from Hardy­Weinberg equilibrium compared 
with its alternatives. We estimated the per­allele ORs and 95% confidence 
intervals for all tested SNPs. The genome­wide distributions of P values were 
examined using quantile­quantile plots, before and after exclusion of the HLA 
region (Supplementary Fig. 1). The assessment of population stratification 
in the discovery cohort is described in Supplementary Note, Supplementary 
Table 3 and Supplementary Figure 2.
False discovery rate and power analysis. The calculation of positive false 
discovery rate (pFDR) was carried out using the Q­value package (R). The 
proportion of SNPs that were truly null (Πo) was estimated at 0.991 using the 
empirical distribution of genome­wide P values20. The Q value of 0.10 (pFDR 
of 10%) corresponded to the P value of 1.3 × 10−5 (Supplementary Fig. 3). 
This Q­value threshold defined 65 top SNPs that were subsequently analyzed 
for replication. The power analysis was carried out using methods described45. 
The calculations were carried out under the following assumptions: a disease 
prevalence of 1%; an additive risk model for stage I (discovery) with sample size 
of 1,000 cases and 1,000 controls and stage II (follow­up) with sample size of 
2,000 cases and 2,000 controls; a follow­up significance threshold of 1.3 × 10−5; 
and joint (stage I and II) significance level of 5 × 10−8. The joint power of our 
study design (Supplementary Table 4) was calculated for a range of disease 
allele frequencies (0.10–0.50) and effect sizes (genotypic risk ratio 1.10–1.80). 
The effect sizes detectable at α = 5 × 10−8 and a power of 0.80 in the joint 
analysis were estimated using CaTS software45.
Selection of SNPs for follow-up. The 65 SNPs that reached our Q­value 
threshold were first clustered into ten distinct loci on the basis of their physi­
cal location and regional patterns of LD. The correctness of genotype calls was 
verified for each SNP individually by visual inspection of the Illumina cluster 
plots. Conditional logistic regression analysis was carried out to confirm cor­
rect SNP grouping and detect independence signals. These analyses suggested 
three distinct loci on chromosome 6p21 and two distinct loci on chromosome 
22q12.2. The SNPs with the lowest P value within each locus were selected for 
follow up. The selection of the second SNP for back­up genotyping was based 
mainly on its strength of association, high LD with the top­scoring SNP in 
European and Chinese HapMap populations, robustness of Illumina clustering 
plots and high genotyping rate. In total, we selected 20 representative SNPs 
for genotyping in 2,013 cases and 1,951 controls recruited for stage 2 of the 
study. Genotyping and genotype quality control in the follow­up cohorts is 
described in Supplementary Note.
Association analyses across multiple cohorts. Results across multiple cohorts 
were combined using a stratified trend test with Mentel’s extension of the 
Cochran­Armitage test (snpMatrix package, R)46. We tested for heterogeneity 
across cohorts with the heterogeneity index (I2), and by carrying out Cochran’s 
Q heterogeneity test. To ensure findings were robust to methodology, we also 
combined the per­allele effect estimates using Cochran­Mantel­Haenszel 
stratified analysis, as well as an inverse variance­weighted method under 
a fixed­effects model. The results were concordant regardless of the meta­ 
analytic method used.
Conditional analyses. We carried out stepwise logistic regression after con­
trolling for the genotypes of the conditioning SNPs using PLINK (v1.07). The 
adjusted (conditioned) effect estimates were then combined across cohorts by 
adding cohort information as an additional covariate in the stratified analysis 
(Table 3 and Supplementary Table 8). A similar approach was used for the 
conditional analysis of classical HLA alleles (Supplementary Table 10).
Haplotype-based association at CFH locus. These analyses were carried 
out in PLINK v1.07. Haplotypes were phased across the CFH locus in the 
Beijing cohort (Fig. 3b and Supplementary Fig. 6) and haplotype frequen­
cies were estimated in the cases and controls separately, as well as jointly 
in the entire cohort. Only the haplotypes with overall frequency >1% were 
included in association analyses. The P values were derived for tests of 
association of one haplotype versus all others. The ORs and the correspond­
ing 95% confidence intervals were estimated in reference to the AMD risk 
haplotype (H­1; Fig. 3b), which has an identical frequency between cases 
and controls.
Imputation and association analysis of classical HLA alleles. The HLA 
classical alleles at DQB1, DQA1 and DRB1 loci were imputed on the basis 
of the genotype data from the Beijing cohort (Supplementary Tables 
9,10). In short, the genotype data were first phased using BEAGLE47 
and pairwise inflammatory bowel disease status was determined using 
GERMLINE software48. The HLA classical allele status and genotype data 
of the HapMap Han Chinese individuals were used as a reference panel 
(see URLs)21. The imputation was carried out using the HLA­via­IBD soft­
ware (see URLs). The accuracy of the imputation procedure was tested by 
direct sequencing of the informative coding segments of HLA-DQB1 gene 
in a random subset of 420 samples. This demonstrated that imputation had 
57% sensitivity and 96% specificity for identifying the HLA-DQB1*602 
alleles (Supplementary Table 11).
Risk score discovery and validation. Among the five independent regions 
of association, alleles with lower frequency conveyed a protective effect. 
Therefore, the risk score model was based on protective genotypes for the top 
five independent and most strongly associated SNPs (rs9275596, rs9357155, 
rs1883414, rs2412971 and rs6677604). The risk score was calculated as a 
weighted sum of the number of protective alleles at each locus multiplied by 
the log of the OR for each of the individual loci for a specific cohort. Only 
individuals with nonmissing genotypes for all ten alleles were included in this 
analysis (Table 4 and Supplementary Table 13). The predictive risk score 
models were built using association results for each of the three model­build­
ing cohorts and were validated by testing their predictive properties against all 
other cohorts (target cohorts, Supplementary Table 14 and Supplementary 
Fig. 7). The percentage of the total variance in disease state explained by the 
risk score was estimated by Nagelkerke’s pseudo r2 from the logistic regression 
model with the risk score as a quantitative predictor and disease state as an 
outcome. The C­statistic was estimated as an area under the receiver operating 
characteristic curve provided by the above logistic model. These analyses were 
carried out with SPSS Statistics version 17.0.
Distributions of protective alleles. Each individual study participant was 
scored for the number of protective alleles and the distributions of protec­
tive alleles were compared between groups of various ancestries (Fig. 4). 
Only individuals with complete genotype information were included. 
Because relatively few individuals had five or more protective alleles, they 
were binned into a single category for the purpose of statistical testing and a 
χ2 goodness­of­fit test was used to derive P values. Analysis of the HapMap 
release 23 data set included 30 unrelated individuals from Yoruba in Ibadan, 
Nigeria (YRI), 30 unrelated Utah residents with ancestry from northern 
and western Europe (CEU), and a combined group of 45 unrelated Japanese 
individuals from Tokyo (JPT) and 45 Han Chinese from Beijing (CHB). 
The genotype data were downloaded directly from the HapMap Project 
website (see URLs). Our exploratory association analyses of protective 
alleles with clinical subphenotypes are described in Supplementary Note 
and Supplementary Table 15.
Common copy number polymorphisms analysis. For the purpose of 
this analysis, we used publicly available CNP discovery data obtained with 
2.1 million NimbleGen CGH arrays49,50. We identified 1,051 SNPs present 
on the Illumina HumanHap 610K chip that tag known common (>1%) copy 
number variations at r2 > 0.8. The genotypes for these SNPs were extracted 
from the data set and analyzed separately for association with the disease state 
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(Supplementary Fig. 4 and Supplementary Table 12). These SNPs underwent 
all quality control steps as outlined above before association analysis. A simple 
1­degree­of­freedom χ2 allelic test was used to screen for association (PLINK) 
and the results were ranked and visualized using a quantile­quantile plot (R). 
The top associated CNPs were validated using quantitative real­time PCR.
Quantitative real-time PCR. Quantitative real­time PCR was carried out on 
genomic DNA using the iQ5 Real­Time PCR Detection System (Bio­Rad) and 
amplification was achieved using SYBR Green Supermix (Bio­Rad) with a stand­
ard two­step amplification protocol. All samples were analyzed in triplicate. Three 
amplicons spanning CFHR1 and CFHR3 were tested and the signal was normal­
ized to an amplicon in B­actin (Supplementary Table 17). Pooled DNA from ten 
individuals homozygous for G alleles at rs6677604 was used as reference.
Protein blotting. Diluted plasma samples were separated on 4–15% Ready Gel 
(Bio­Rad), transferred to PVDF membranes (Millipore), and protein blotted 
with primary antibodies to CFH (AbD Serotec) and CFHR1 (R&D Systems) 
using standard protocols.
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